Related Experiment Video
Updated: Jul 18, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Comparison of effects of fibrates in patients with hypertriglyceridemia
Murat Suher1, Eyüp Koç, Berrin Camur
1Department of Internal Medicine, Ankara Atatürk Education and Research Hospital, Ankara, Turkey.
Abstract:
It has long been known that antihyperlipidemic agents categorized as fibrates are capable of reducing triglyceride concentrations, although the superiority of one over another remains questionable. In the present study, investigators compared treatment results from various fibrates. In all, 60 patients aged 54.1+/-12 y with hypertriglyceridemia were included in the study. Patients who had increased values on liver function tests, had been given a diagnosis of hypothyroidism or chronic renal failure, and who needed statin medication were excluded. Patients were divided into 4 groups according to the medication given; treatments consisted of Lipanthyl 1 x 1, Lipofentrade mark 1 x 1, Lopid 1 x 1, and Lopid 2 x 1. Biochemical and hematologic parameters of patients were recorded at the first visit and at the end of the 2-mo treatment period. A total of 18 patients (30%) were given Lipanthyl 1 x 1, 14 (23.3%) received Lipofen 1 x 1, 16 (26.7%) were treated with Lopid 1 x 1, and 12 (20%) were given Lopid 2 x 1. Effects on triglyceride values were assessed in all groups. Lopid 1 x 1 and Lopid 2 x 1 produced significant decreases in triglyceride values. Most adverse effects were reported in the group given Lopid 2 x 1. In the treatment of hypertriglyceridemia, fibrates have similar effects on tolerability and reliability. However, study findings indicated that Lopid 1 x 1 and 2 x 1 treatments have greater efficacy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Atherosclerosis III: Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
